[go: up one dir, main page]

SK12002003A3 - Novel tyrosine kinase inhibitors - Google Patents

Novel tyrosine kinase inhibitors Download PDF

Info

Publication number
SK12002003A3
SK12002003A3 SK12002003A SK12002003A SK12002003A3 SK 12002003 A3 SK12002003 A3 SK 12002003A3 SK 12002003 A SK12002003 A SK 12002003A SK 12002003 A SK12002003 A SK 12002003A SK 12002003 A3 SK12002003 A3 SK 12002003A3
Authority
SK
Slovakia
Prior art keywords
methyl
pyridin
benzoimidazol
group
hydroxy
Prior art date
Application number
SK12002003A
Other languages
English (en)
Slovak (sk)
Inventor
Mark WITTMAN
Neelakantan Balasubramanian
Upender Velaparthi
Kurt Zimmermann
Mark G Saulnier
Peiying Liu
Xiaopeng Sang
David B Frennesson
Karen M Stoffan
James G Tarrant
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SK12002003A3 publication Critical patent/SK12002003A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK12002003A 2001-03-28 2002-03-26 Novel tyrosine kinase inhibitors SK12002003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932701P 2001-03-28 2001-03-28
PCT/US2002/009402 WO2002079192A1 (fr) 2001-03-28 2002-03-26 Nouveaux inhibiteurs de la tyrosine kinase

Publications (1)

Publication Number Publication Date
SK12002003A3 true SK12002003A3 (en) 2004-10-05

Family

ID=23068491

Family Applications (1)

Application Number Title Priority Date Filing Date
SK12002003A SK12002003A3 (en) 2001-03-28 2002-03-26 Novel tyrosine kinase inhibitors

Country Status (25)

Country Link
EP (1) EP1381598A4 (fr)
JP (1) JP2004534010A (fr)
KR (1) KR20030083016A (fr)
CN (1) CN1514833A (fr)
AR (1) AR035804A1 (fr)
BG (1) BG108206A (fr)
BR (1) BR0208373A (fr)
CA (1) CA2442428A1 (fr)
CZ (1) CZ20032615A3 (fr)
EE (1) EE200300475A (fr)
GE (1) GEP20053660B (fr)
HR (1) HRP20030844A2 (fr)
HU (1) HUP0400323A2 (fr)
IL (1) IL158041A0 (fr)
IS (1) IS6968A (fr)
MX (1) MXPA03008690A (fr)
NO (1) NO20034308L (fr)
PE (1) PE20021015A1 (fr)
PL (1) PL373300A1 (fr)
RU (1) RU2003131693A (fr)
SK (1) SK12002003A3 (fr)
UY (1) UY27234A1 (fr)
WO (1) WO2002079192A1 (fr)
YU (1) YU84603A (fr)
ZA (1) ZA200307466B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
IL163515A0 (en) 2002-03-01 2005-12-18 Bristol Myers Squibb Co Transgenic non-human mammals
CA2488635C (fr) * 2002-06-12 2012-10-23 Abbott Laboratories Antagonistes du recepteur de l'hormone de melano-concentration
WO2004050033A2 (fr) * 2002-12-02 2004-06-17 Arqule, Inc. Methodes de traitement de cancers
WO2004063151A2 (fr) 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Nouveaux inhibiteurs de tyrosine kinase
JP2006516626A (ja) * 2003-01-28 2006-07-06 スミスクライン ビーチャム コーポレーション 化学的化合物
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
CN1960993A (zh) 2004-04-02 2007-05-09 Osi制药公司 6,6-双环取代的杂双环蛋白激酶抑制剂
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8101770B2 (en) * 2004-12-16 2012-01-24 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US7393667B2 (en) 2005-05-31 2008-07-01 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2431050T3 (es) 2005-08-04 2013-11-22 Sirtris Pharmaceuticals, Inc. Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7786120B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
CA2620352A1 (fr) * 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated Pyrid-2-ones disubstituees en 3, 5 inhibitrices de la famille tec des tyrosine kinases non receptrices
US7691885B2 (en) 2005-08-29 2010-04-06 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
WO2007026720A1 (fr) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. Derive de pyrazole a noyau condense
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007145203A1 (fr) * 2006-06-13 2007-12-21 Daiichi Fine Chemical Co., Ltd. 2-amino-1-(4-fluorophenyl) éthanol optiquement actif
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (fr) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Dérivés tricycliques de lactame, leur fabrication et leur emploi en tant qu'agents pharmaceutiques
WO2008025526A1 (fr) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Dérivés d'indole, fabrication de ceux-ci et utilisation comme agents pharmaceutiques
US8492328B2 (en) 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CA2690064A1 (fr) 2007-06-25 2008-12-31 Guy Georges Derives amido du benzimidazole en tant qu'inhibiteurs de kinase
EP2065380A1 (fr) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Dérivés de pyridoneamide comme inhibiteurs de focal adhesion kinase (FAK) et leur utilisation pour le traitement du cancer
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
ES2461799T3 (es) * 2008-01-22 2014-05-21 Vernalis (R&D) Ltd. Derivados de indolil-piridona que tienen actividad inhibidora de la quinasa de control 1
WO2009143051A1 (fr) 2008-05-19 2009-11-26 Osi Pharmaceuticals, Inc. Imidazopyrazines et imidazotriazines substituées
WO2010071853A1 (fr) 2008-12-19 2010-06-24 Sirtris Pharmaceuticals, Inc. Composés thiazolopyridines de modulation des sirtuines
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
MX2011011025A (es) 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparacion de c-piracin-metilaminas.
MX2011012629A (es) * 2009-05-27 2012-03-06 Abbott Lab Inhibidores de actividad de cinasa tipo pirimidina.
WO2011053779A2 (fr) 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Méthodes pour traiter un cancer chez des patients présentant une résistance à l'inhibiteur d'igf-1r
MY170236A (en) * 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
JP5789888B2 (ja) * 2010-11-01 2015-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
WO2013056069A1 (fr) 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Procédés de sélection et de traitement du cancer chez des patients au moyen d'inhibiteurs de l'igf-1r/ir
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
ES2806135T3 (es) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd Nuevos inhibidores de bromodominios bicíclicos
CA2919948C (fr) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Nouvelles quinazolones en tant qu'inhibiteurs de bromodomaine
CN103936719A (zh) * 2014-05-14 2014-07-23 中国药科大学 苯并咪唑类衍生物制备方法及用途
JP2017525351A (ja) 2014-07-30 2017-09-07 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. 多能性幹細胞の培養用培地
WO2016087936A1 (fr) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Pyridinones substituées utilisées comme inhibiteurs de bromodomaines
HK1245248B (en) 2014-12-11 2020-05-15 恒翼生物医药(上海)股份有限公司 Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
AU2016249537B2 (en) * 2015-04-16 2020-01-30 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives
WO2020152686A1 (fr) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Milieux de culture pour cellules souches pluripotentes
CN117069696B (zh) * 2023-08-17 2024-04-26 中国药科大学 一种双靶点小分子抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
DE50010931D1 (de) * 1999-06-23 2005-09-15 Aventis Pharma Gmbh Substituierte benzimidazole
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO2002079192A1 (fr) 2002-10-10
HUP0400323A2 (hu) 2005-11-28
YU84603A (sh) 2006-03-03
CN1514833A (zh) 2004-07-21
IL158041A0 (en) 2004-03-28
UY27234A1 (es) 2002-10-31
MXPA03008690A (es) 2003-12-12
EP1381598A4 (fr) 2008-03-19
CZ20032615A3 (en) 2004-03-17
PE20021015A1 (es) 2002-11-10
CA2442428A1 (fr) 2002-10-10
JP2004534010A (ja) 2004-11-11
BG108206A (bg) 2004-11-30
PL373300A1 (en) 2005-08-22
HRP20030844A2 (en) 2005-08-31
KR20030083016A (ko) 2003-10-23
EP1381598A1 (fr) 2004-01-21
ZA200307466B (en) 2005-01-13
RU2003131693A (ru) 2005-05-10
EE200300475A (et) 2004-02-16
GEP20053660B (en) 2005-11-10
NO20034308D0 (no) 2003-09-26
BR0208373A (pt) 2005-02-22
NO20034308L (no) 2003-11-26
AR035804A1 (es) 2004-07-14
IS6968A (is) 2003-09-26

Similar Documents

Publication Publication Date Title
SK12002003A3 (en) Novel tyrosine kinase inhibitors
US20040044203A1 (en) Novel tyrosine kinase inhibitors
JP5977779B2 (ja) 2−(2,4,5−置換−アニリノ)ピリミジン化合物
CA2534921C (fr) Composes d'aminotriazole utiles en tant qu'inhibiteurs des proteines kinases
AU2016240033B2 (en) 1-cyano-pyrrolidine compounds as USP30 inhibitors
DE60103935T2 (de) Imidazol-5-yl-2-anilino-pyrimidine als inhibitoren der zellproliferation
TW496863B (en) Inhibitors of farnesyl protein transferase
AU2004212421B2 (en) Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
US7232826B2 (en) Tyrosine kinase inhibitors
US7189716B2 (en) Tyrosine kinase inhibitors
CN112638373A (zh) 细胞周期蛋白依赖性激酶抑制剂
TWI902864B (zh) 新穎二唑系選擇性hdac6抑制劑及其用途
CN115605463B (zh) 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
CN108699057A (zh) 5-取代的2-(吗啉-4-基)-1,7-萘啶
EP1697375A2 (fr) Inhibiteurs heterocycliques de proteine kinase et leurs utilisations
KR20130028732A (ko) 4―아미노피리미딘 유도체 및 아데노신 a2a 수용체 안타고니스트로서의 이들의 용도
PT1569937E (pt) Indazolilpirrolotriazinas modificadas em c-6
WO2016041618A1 (fr) Indazoles substitués et hétérocycles associés
KR20060129040A (ko) 세포 증식 억제제로서의이미다졸로-5-일-2-아닐리노피리미딘
CN105814037B (zh) 作为丙酮酸脱氢酶激酶的抑制剂的n1-(3,3,3-三氟-2-羟基-2-甲基丙酰基)-哌啶衍生物
ES2402855T3 (es) Derivados de cianuro de azol-metilideno y su uso como moduladores de proteína cinasas
AU2002254399A1 (en) Novel tyrosine kinase inhibitors
CA3022793A1 (fr) Derives sulfonamides aromatiques

Legal Events

Date Code Title Description
FC9A Refused patent application